475042-34-3

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 104-88-1 4-chlorobenzaldehyde 
• 57-13-6 urea 

Downstream Products

• 1199944-26-7 ethyl 6-(azidomethyl)-4-(4-chlorophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 

Relevant academic research and scientific papers

Chromene-triazole-pyrimidine based chemosensor therapeutics for thein vivoandin vitrodetection of Fe3+ions

The development of a series of chromene-pyrimidine triad molecules for the selective detection of Fe3+is described. The new chemosensors were synthesized through the sequential use of multicomponent reactions (MCRs) and click chemistry marking its ease and cost effectiveness. The sensor molecules showed turn-off fluorescence towards Fe3+with an extremely low limit of detection (LOI) and a strong affinity to cancer causing CDK2 proteins with binding energy closer to -9.8 kcal mol-1as indicated by the molecular docking studies. The free hydrophilic handles present on the sensors are advantageous for binding with cellular Fe3+demonstrating the potential of these molecules as therapeutics for iron overloading diseases. The therapeutic potential is further illustratedviacytotoxicity studies against the human cervical cancer cell line HeLa, which showed a very low IC50 value of 15 μg mL-1

Design and synthesis of substituted dihydropyrimidinone derivatives as cytotoxic and tubulin polymerization inhibitors

An operationally simple Biginelli protocol was employed for the synthesis of new C6-carbon based aryl α-haloacrylamide-linked dihydropyrimidinone derivatives. The synthesized compounds were appraised for their in vitro antiproliferative potential against a selected panel of human cancer cell lines especially MCF-7 (human breast cancer), MDA-MB-231 (human breast cancer), HCT-116 (human colon cancer), HCT-15 (human colorectal adenocarcinoma), HT-29 (human colon adenocarcinoma) and DU145 (human prostate cancer) along with normal lung fibroblasts (HFL-1). Preferably, compounds containing α-haloacrylamide (10a-g) functionality were found to exhibit most significant cytotoxicity (IC50 value 0.54 ± 0.12 to 8.35 ± 0.82 μM) against the listed cancer cell lines, particularly towards breast cancer cell lines MCF-7 and MDA-MB-231 (IC50 value 0.54 ± 0.12 to 3.70 ± 0.24 μM). In the seam of synthesized compounds, compound 10f exhibited potent antiproliferative activity against breast cancer cell lines namely MCF-7 (IC50 value 0.54 ± 0.12 μM) and MDA-MB-231 (IC50 value 1.18 ± 0.32 μM). Further to understand the underlying apoptosis mechanisms, different staining techniques such as AO/EB, DCFDA, and DAPI staining were performed. To know the extent of apoptosis and loss of mitochondrial membrane potential in MCF-7 cell lines, annexin V-FITC/PI and JC-1 were performed. Cell cycle analysis revealed that compound 10f arrested the cells at G2/M phase in a dose-dependent manner. The compound 10f also found to exhibit significant inhibition of tubulin polymerization (IC50 of 6.91 ± 0.43 μM) with microtubule destabilizing properties. Molecular docking studies also revealed that compound 10f efficiently interacted with critical catalytically active residues Ser178, Val238, and Val318 of the α/β-tubulin by a hydrogen bond.

Synthesis of new polyfunctional 5,6,7,8-tetrahydroimidazo-[1,5-c]pyrimidin- 5-ones by the aza-wittig reaction followed by intramolecular cyclization and 1,3-prototropic shift

Ethyl 2-oxo-6-[(triphenyl-λ5-phosphanylidene)aminomethyl] -1,2,3,4-tetrahydropyrimidine-5-carboxylates reacted with organic isocyanates according to the aza-Wittig pattern, and the subsequent intramolecular ring closure and 1,3-H shift resulted